Biblioteca CRAI Dulce Chacón - Universidad Europea de Madrid

CRAI Library - Madrid
Your cart is empty.
My folder ( items) | My account
Image from Google Jackets

Essentials of SGLT2 inhibitors in diabetes / Miles Fisher, Gerard McKay

By: Fisher, Miles, autor
Contributor(s): McKay, Gerard A., autor
Material type: materialTypeLabelE-bookPublisher: Cham : Adis, [2016]Copyright date: 2017Description: 1 recurso en línea (77 páginas).ISBN: 3319432966; 9783319432960.Subject: DiabetesOnline resources: Acceso a este recurso digital (usuarios Universidad Europea de Madrid)Digital Resources
Contents:
Biographies; Contents; Editors; Contributors; Chapter 1: Overview of Type 2 Diabetes; 1.1 Epidemiology and Global Disease Burden; 1.2 Diagnostic Criteria for Diabetes; 1.3 Glucose Homeostasis; 1.4 Pathogenesis of Type 2 Diabetes; 1.5 Risk Factors for the Development of Diabetes; 1.6 Clinical Features of Diabetes; 1.7 Complications of Diabetes; References; Chapter 2: SGLT2 Inhibitors for Treating Diabetes; 2.1 Mode of Action and Clinical Pharmacology; 2.2 Drug Development and Major Clinical Trials; 2.2.1 Phlorizin; 2.2.2 Glycemic Effects of Dapagliflozin.
2.2.3 Glycemic Effects of Canagliflozin2.2.4 Glycemic Effects of Empagliflozin; 2.2.5 Glycemic Effects of SGLT2 Inhibitors: Where Are We Now?; 2.3 Effects of SGLT2 Inhibitors on Body Weight; 2.4 Effects of SGLT Inhibitors on Blood Pressure; 2.5 Adverse Effects and Safety; 2.5.1 Hypoglycemia with SGLT2 Inhibitors; 2.5.2 Genital Infections; 2.5.3 Volume Depletion; 2.5.4 Effects of SGLT2 Inhibitors on Lipids; 2.5.5 Effects on Renal Function; 2.5.6 Fractures; 2.6 Ketoacidosis; References; Chapter 3: Guidelines for the Treatment of Type 2 Diabetes Mellitus; 3.1 Introduction.
3.2 International Diabetes Federation Guidelines3.3 Joint American Diabetes Association and European Association for the Study of Diabetes Position Statement; 3.3.1 Update to the Joint ADA/EASD Position Statement; 3.4 Country Case Study: Developing Guidelines in the UK; 3.5 Conclusion; References; Chapter 4: Using SGLT2 Inhibitors in Special Populations; 4.1 Introduction; 4.2 SGLT2 Inhibitors in Patients with Cardiovascular Disease; 4.2.1 EMPA-REG OUTCOME; 4.2.2 Cardiovascular Trials with Other SGLT2 Inhibitors; 4.3 SGLT2 Inhibitors in Patients with Chronic Kidney Disease.
4.3.1 Cohort Analysis of Patients Treated with Canagliflozin4.3.2 Renoprotective Aspects of SGLT2 Inhibitors; 4.3.3 Renal Outcome Studies with SGLT2 Inhibitors; 4.4 SGLT2 Inhibitors in Older Patients with Type 2 Diabetes; 4.4.1 Dapagliflozin in Older Patients with Type 2 Diabetes; 4.4.2 Canagliflozin in Older Patients with Type 2 Diabetes; 4.5 SGLT2 Inhibitors in Type 1 Diabetes; 4.5.1 Empagliflozin in Type 1 Diabetes; 4.5.2 Dapaglifozin in Type 1 Diabetes; 4.5.3 Sotagliflozin in Type 1 Diabetes; 4.5.4 Future Prospects in Type 1 Diabetes; References.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Call number Status Date due Barcode Item holds
LIBRO-E NO PRÉSTAMO LIBRO-E NO PRÉSTAMO Madrid Digital Acceso Electrónico (UEM) Ciencias de la Salud RC662.18 .F574 2016 EB (Browse shelf(Opens below)) Acceso electrónico eBook.20022490
Total holds: 0

SpringerLink

Incluye referencias bibliográficas

Biographies; Contents; Editors; Contributors; Chapter 1: Overview of Type 2 Diabetes; 1.1 Epidemiology and Global Disease Burden; 1.2 Diagnostic Criteria for Diabetes; 1.3 Glucose Homeostasis; 1.4 Pathogenesis of Type 2 Diabetes; 1.5 Risk Factors for the Development of Diabetes; 1.6 Clinical Features of Diabetes; 1.7 Complications of Diabetes; References; Chapter 2: SGLT2 Inhibitors for Treating Diabetes; 2.1 Mode of Action and Clinical Pharmacology; 2.2 Drug Development and Major Clinical Trials; 2.2.1 Phlorizin; 2.2.2 Glycemic Effects of Dapagliflozin.

2.2.3 Glycemic Effects of Canagliflozin2.2.4 Glycemic Effects of Empagliflozin; 2.2.5 Glycemic Effects of SGLT2 Inhibitors: Where Are We Now?; 2.3 Effects of SGLT2 Inhibitors on Body Weight; 2.4 Effects of SGLT Inhibitors on Blood Pressure; 2.5 Adverse Effects and Safety; 2.5.1 Hypoglycemia with SGLT2 Inhibitors; 2.5.2 Genital Infections; 2.5.3 Volume Depletion; 2.5.4 Effects of SGLT2 Inhibitors on Lipids; 2.5.5 Effects on Renal Function; 2.5.6 Fractures; 2.6 Ketoacidosis; References; Chapter 3: Guidelines for the Treatment of Type 2 Diabetes Mellitus; 3.1 Introduction.

3.2 International Diabetes Federation Guidelines3.3 Joint American Diabetes Association and European Association for the Study of Diabetes Position Statement; 3.3.1 Update to the Joint ADA/EASD Position Statement; 3.4 Country Case Study: Developing Guidelines in the UK; 3.5 Conclusion; References; Chapter 4: Using SGLT2 Inhibitors in Special Populations; 4.1 Introduction; 4.2 SGLT2 Inhibitors in Patients with Cardiovascular Disease; 4.2.1 EMPA-REG OUTCOME; 4.2.2 Cardiovascular Trials with Other SGLT2 Inhibitors; 4.3 SGLT2 Inhibitors in Patients with Chronic Kidney Disease.

4.3.1 Cohort Analysis of Patients Treated with Canagliflozin4.3.2 Renoprotective Aspects of SGLT2 Inhibitors; 4.3.3 Renal Outcome Studies with SGLT2 Inhibitors; 4.4 SGLT2 Inhibitors in Older Patients with Type 2 Diabetes; 4.4.1 Dapagliflozin in Older Patients with Type 2 Diabetes; 4.4.2 Canagliflozin in Older Patients with Type 2 Diabetes; 4.5 SGLT2 Inhibitors in Type 1 Diabetes; 4.5.1 Empagliflozin in Type 1 Diabetes; 4.5.2 Dapaglifozin in Type 1 Diabetes; 4.5.3 Sotagliflozin in Type 1 Diabetes; 4.5.4 Future Prospects in Type 1 Diabetes; References.

Versión impresa

There are no comments on this title.

to post a comment.
Share